P87 Dynamic contrast-enhanced MRI (DCE-MRI) as imaging biomarker in non-small cell lung cancer (NSCLC)

Boogaart, V. van den; Smit, Egbert F.; Groen, Harry J.M.; Marcus, T.; Kappert, Peter; Backes, Walter H.; Dingemans, A.

doi:10.1016/s1359-6349(08)70092-2

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quantitative imaging has gradually become an important tool in oncological care. A broad number of published studies in solid cancer outside the lung have shown that DCE-MRI may provide important predictive and prognostic biomarker and allows early non-invasive treatment monitoring in various solid cancers [13][14][15][16][17][18][19]. However, the standardization of DCE-MRI and the use of (semi-)quantitative pharmacokinetic models is still an issue for the implementation of DCE-MRI in clinical routine.…”

Section: Discussionmentioning

confidence: 99%

Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient Ktrans in lung cancer

et al. 2022

View full text Add to dashboard Cite

Dynamic contrast enhanced MRI (DCE-MRI) is a useful method to monitor therapy assessment in malignancies but must be reliable and comparable for successful clinical use. The aim of this study was to evaluate the inter- and intrarater reproducibility of DCE-MRI in lung cancer. At this IRB approved single centre study 40 patients with lung cancer underwent up to 5 sequential DCE-MRI examinations. DCE-MRI were performed using a 3.0T system. The volume transfer constant Ktrans was assessed by three readers using the two-compartment Tofts model. Inter- and intrarater reliability and agreement was calculated by wCV, ICC and their 95% confident intervals. DCE-MRI allowed a quantitative measurement of Ktrans in 107 tumors where 91 were primary carcinomas or intrapulmonary metastases and 16 were extrapulmonary metastases. Ktrans showed moderate to good interrater reliability in overall measurements (ICC 0.716–0.841; wCV 30.3–38.4%). Ktrans in pulmonary lesions ≥ 3 cm showed a good to excellent reliability (ICC 0.773–0.907; wCV 23.0–29.4%) compared to pulmonary lesions < 3 cm showing a moderate to good reliability (ICC 0.710–0.889; wCV 31.6–48.7%). Ktrans in intrapulmonary lesions showed a good reliability (ICC 0.761–0.873; wCV 28.9–37.5%) compared to extrapulmonary lesions with a poor to moderate reliability (ICC 0.018–0.680; wCV 28.1–51.8%). The overall intrarater agreement was moderate to good (ICC 0.607–0.795; wCV 24.6–30.4%). With Ktrans, DCE MRI offers a reliable quantitative biomarker for early non-invasive therapy assessment in lung cancer patients, but with a coefficient of variation of up to 48.7% in smaller lung lesions.

show abstract